Clinical Trial Update: First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 first-in-human study evaluating mirvetuximab soravtansine in adults with ovarian cancer and other FOLR1-positive solid tumors; study completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Folate Receptor 1 -positive Solid Tumors
• Ovarian Cancer

Drugs mentioned

• Mirvetuximab soravtansine (mirvetuximab soravtansine)

Snippet

Sponsor: ImmunoGen, Inc. | Conditions: Tumors | Phase 1 | Status: COMPLETED | Results posted: 2021-02-17